AN2 Therapeutics
ANTX
54 hedge funds and large institutions have $60.9M invested in AN2 Therapeutics in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 15 closing their positions.
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
6% more funds holding
Funds holding: 51 → 54 (+3)
5.59% less ownership
Funds ownership: 68.58% → 62.99% (-5.6%)
29% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 17
85% less capital invested
Capital invested by funds: $418M → $60.9M (-$357M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$4.77M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$2.39M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.78M |
| 4 |
Walleye Capital
New York
|
+$1.44M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$12.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.84M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$3.53M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$3.24M |
ANTX Hedge Fund Activity: Q1 2024 in Review
54 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q1 2024, worth a combined $60.9M — down 85% from $418M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ANTX positions and 15 closed out — a net gain of 3 holders — while 12 added to existing stakes and 17 trimmed.
The largest buyer was Octagon Capital Advisors, adding an estimated $4.77M. The largest seller was TCG Crossover Management, cutting an estimated $12.2M.
- 54 institutional investors held AN2 Therapeutics (ANTX) as of Q1 2024, up from 51 in Q4 2023.
- Funds reported $60.9M of AN2 Therapeutics stock for Q1 2024, down 85% quarter-over-quarter.
- 18 funds opened new AN2 Therapeutics positions in Q1 2024 and 15 closed out, a net change of +3 holders.
- The largest AN2 Therapeutics buyer in Q1 2024 was Octagon Capital Advisors, an estimated $4.77M added.
- The largest AN2 Therapeutics seller in Q1 2024 was TCG Crossover Management, an estimated $12.2M sold.
Based on aggregated 13F filings for Q1 2024.